Trial Profile

A clinical study of SG-5-00455in IBD

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SG 5 00455 (Primary)
Indications Inflammatory bowel diseases
Focus Adverse reactions
Sponsors Second Genome

Most Recent Events

24 May 2022 According to a Second Genome media release, the Company expects to file an investigational new drug (IND) application with the U.S. FDA in late 2022
18 Feb 2022 According to a Second Genome media release, the Company expects to file an investigational new drug (IND) application with the U.S. FDA in the second half of 2022, with clinical data expected in 2023.
11 Jan 2021 According to a Second Genome media release, the lead program SG-2-0776 in IBD expected to enter clinical development in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com